Skip to main content
Funded Studies

Jonas Hannestad, MD, PhD

Vice President of Clinical Development at Alkahest, Inc.

Location: San Carlos, CA United States

Dr. Hannestad has more than 20 years of experience in the field of neuroscience at both academic and biopharmaceutical organizations and is a noted authority in PET imaging in neuroinflammatory and other neurological disorders including the effect of systemic factors on the brain.  Dr. Hannestad joined Alkahest from Denali Therapeutics, where he worked on the LRRK2 programs. Previously, at UCB Pharma he worked on two PD programs: the adenosine 2A receptor antagonist tozadenant and the alpha-synuclein modulator NPT200-11.

He received his MD from Universidad de Oviedo and a PhD from the University of Messina, and then completed a fellowship at UCLA and residency training in internal medicine and psychiatry at Duke University and Yale University.

In addition to his role at Alkahest, Dr. Hannestad also maintains a position as Adjunct Assistant Professor of Psychiatry at the Yale University School of Medicine.

Associated Grants

  • Clinical Development of AKST4290 as a Novel Parkinson’s Therapeutic


  • Safety and Tolerability of GRF6021 Infusions in People with Parkinson's Disease and Cognitive Impairment


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.